Market research
HTGM HTG Molecular Diagnostics Inc
NASDAQ USD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 1M
- P/E ratio
- Not available
- Analyst target
- 6
- Dividend yield
- 0.0%
- Beta
- 0.99
Profile
Company facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Healthcare Equipment & Supplies
- ISIN
- US40434H2031
- Market cap
- 1M
- P/E ratio
- Not available
- Analyst target
- 6
- Dividend yield
- 0.0%
- Beta
- 0.99
About
About HTG Molecular Diagnostics Inc
HTG Molecular Diagnostics, Inc. a life sciences company, focuses on the precision medicine. The company offers instruments; consumables; and software that automate sample processing and profiles various molecular targets. Its marketed molecular profiling panels include HTG Transcriptome Panel; HTG EdgeSeq precision immuno-oncology panel; HTG EdgeSeq miRNA whole-transcriptome assay; HTG EdgeSeq DLBCL cell of origin assay EU; HTG EdgeSeq Oncology Biomarker Panel; HTG immune response panel; and HTG mouse mRNA tumor response panel. The company distributes its instruments and consumables directly in the United States and Europe; and through distributors in parts of Europe and internationally. It serves biopharmaceutical companies, academic research centers, and molecular testing laboratories. The company was formerly known as HTG, Inc. and changed its name to HTG Molecular Diagnostics, Inc. in March 2011. HTG Molecular Diagnostics, Inc. was incorporated in 1997 and is based in Tucson, Arizona. On June 5, 2023, HTG Molecular Diagnostics, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the HTGM discussion.
5 years, 4 months ago
HTG Molecular Diagnostics, Inc is currently in a long term uptrend where the price is trading 4.3% above its 200 day moving average.
From a valuation standpoint, the stock is 99.8% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 3.1.
HTG Molecular Diagnostics, Inc's total revenue sank by 46.2% to $3M since the same quarter in the previous year.
Its net income has increased by 99.9% to $-4K since the same quarter in the previous year.
Finally, its free cash flow grew by 14.8% to $-4M since the same quarter in the previous year.
Based on the above factors, HTG Molecular Diagnostics, Inc gets an overall score of 4/5.